$QNCX News

Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target

Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) Estimate

Quince Therapeutics Says Brigette Roberts Conditionally Appointed As CEO; John Militello Conditionally Appointed As CFO

Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4

Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy

Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics Inc - M&A Call - Slideshow

Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

Quince Therapeutics Announces Acquisition Of Orphai Therapeutics In Stock-For-Stock Deal; Quince Enters Concurrent Private Placement Agreement To Raise Up To $187M

Quince Therapeutics Reports Phase 2a Data For LAM-001 In Pulmonary Hypertension-Associated ILD, Demonstrated Clinically Meaningful Improvement In Multiple Assessments Of Lung Function, Including Improvement In 6MWD Of 67.4 Meters And PVR Reduction Of 33.9% At 24 Weeks; Phase 2b Trial In PH-ILD To Initiate In Mid-2026, With Topline Data Anticipated In Q1 2028

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Quince Therapeutics shares are trading higher after the company announced a settlement of its outstanding obligations under a loan from the European Investment Bank for a payment of $5.5 million.

Quince Therapeutics Settles $5.5M Loan Under Its Obligations From European Investment Bank